Autres langues Camurus AB

Actions

CAMX

SE0007692850

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:51 02/05/2024			Varia. 5j.	Varia. 1 janv.
494,4 ^SEK	-0,76 %		+2,32 %	-8,10 %

02/04	Camurus AB (Publ) annonce la démission de membres de son conseil d'administration	CI
05/03	La demande de nouveau médicament de Camurus pour le traitement de l'acromégalie acceptée par la FDA américaine	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17/04
Notice of annual general meeting 2024 in Camurus (publ)	02/04
Camurus AB Announces Board Resignations	02/04
Camurus Annual Report for 2023	28/03
Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA	05/03
Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly	05/03
Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly	05/03
OPINIONES DE LOS ANALISTAS DEL DÍA : Acciona, Amadeus, Acs, Endesa, Ferrari, Heineken, Iberdrola, Prosegur, Salvatore Ferragamo...	04/03
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Nordic Shares Rose Thursday; Tomra Systems Climbed Highest	15/02
Camurus' Full Year Report 2023	15/02
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Camurus AB Provides Earnings Guidance for the Full Year 2024	15/02
Camurus appoints Behshad Sheldon as President of Camurus Inc.	13/02
Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024	13/02
Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease	08/02
Camurus AB Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease	08/02
Nordic Stocks Rose Thursday; Kinnevik Series B Topped Leaders	18/01
Camurus has carried out a directed share issue of 2,000,000 shares at a subscription price of SEK 545 per share, raising gross proceeds of SEK 1,090 million	18/01
Camurus intends to carry out a directed share issue of approximately 2 million shares and provides preliminary financial information for FY 2023	17/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Camurus AB

Actions

CAMX

SE0007692850

Autres langues

Filtres